Infectious Disease Clinical Trials Update: Week 15, 2026

Published April 10, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

OPV as Potential Protection Against COVID-19

A completed Phase 4 trial in Guinea-Bissau tested whether the oral polio vaccine (OPV) could reduce illness and death related to COVID-19 in adults over 50. This study explored if an existing vaccine might offer extra protection for older adults against COVID-19, which remains important as this group faces higher risks. The results from this trial provide valuable information on whether the OPV could be used alongside other COVID-19 measures to help keep older adults safer.

Immunobridging Study of 9-Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)

This Phase 3 trial evaluated the immune response and safety of the 9-valent HPV vaccine in healthy Chinese females aged 9 to 45. The vaccine targets multiple types of HPV, which can cause infections leading to serious health problems such as cervical cancer. The study’s completion with available results marks an important step toward broader protection against HPV infections in a large population, potentially helping to reduce HPV-related diseases in China and beyond.

A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age

This ongoing Phase 4 study in South Korea is testing a meningococcal group B vaccine in healthy infants starting at 2 months old. By focusing on safety and immune response, the trial aims to provide evidence for a vaccine schedule that includes two primary doses plus a booster. If effective, this vaccine could offer better protection for young children against meningitis caused by Neisseria meningitidis, a serious and sometimes deadly infection.

Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)

This Phase 2 trial completed in France studied two types of flu vaccines in people living with HIV to assess their safety and ability to trigger an immune response. People with HIV often have weaker immune systems, so finding effective flu vaccines is important for their health. Although results are still pending, this study could help identify better flu protection options for this group in the future.

Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study

This Phase 3 trial is testing two existing drugs to see if they can improve symptoms like fatigue and breathing difficulties in adults with Long Covid. The study is actively recruiting participants across the US, Brazil, and Canada, with treatment lasting three months. If successful, these drugs could provide new ways to manage ongoing symptoms after a COVID-19 infection, offering hope to many people affected by Long Covid.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.